Biosimilars: what the oncologist should know
نویسندگان
چکیده
منابع مشابه
Biosimilars: what clinicians should know.
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United States. Despite an established legal pathway for biosimilars in the European Union since 2005 and increasing and detailed regulatory guidance on data requirements for their development and licensing, many clinicians, particularly oncologists, are reluctant to consider...
متن کاملBiosimilars in rheumatology: what the clinician should know
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalence and non-inferiority statistical approaches, are discussed. Clinical evidence on biosimilars tha...
متن کاملWhat every pediatrician should know about liver transplantation
Liver transplantation is the treatment of choice for children with end-stage liver disease. Improvement in outcomes (allograft and patient survival) has led to widespread use of pediatric LT worldwide. This success is due to improvement in patient selection, transplant surgery, anesthesia/postoperative care and immunosuppression management. This review will focus on different aspects of LT whi...
متن کاملPharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know.
Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-...
متن کاملWhat Clinicians Should Know
Case presentation: A 36-year-old nonsmoking, normotensive South Asian man presented to the emergency department of a community hospital with retrosternal chest pain of 60 minutes’ duration. His 12-lead ECG demonstrated 10 mm of STsegment elevation in leads V2 through V6, and he received fibrinolytic therapy within 90 minutes of symptom onset. His pain resolved, but his ST segments only partiall...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2019
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2018-0728